You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
AstraZeneca
Express Scripts
Harvard Business School
Johnson and Johnson

Last Updated: April 3, 2020

DrugPatentWatch Database Preview

FIBRICOR Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Fibricor, and what generic alternatives are available?

Fibricor is a drug marketed by Athena and is included in one NDA. There are four patents protecting this drug.

The generic ingredient in FIBRICOR is fenofibric acid. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the fenofibric acid profile page.

US ANDA Litigation and Generic Entry Outlook for Fibricor

A generic version of FIBRICOR was approved as fenofibric acid by ANCHEN PHARMS on July 18th, 2013.

  Start Trial

Drug patent expirations by year for FIBRICOR
Drug Prices for FIBRICOR

See drug prices for FIBRICOR

Recent Clinical Trials for FIBRICOR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Mutual Pharmaceutical Company, Inc.Phase 1

See all FIBRICOR clinical trials

Pharmacology for FIBRICOR

US Patents and Regulatory Information for FIBRICOR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Athena FIBRICOR fenofibric acid TABLET;ORAL 022418-001 Aug 14, 2009 RX Yes No   Start Trial   Start Trial   Start Trial
Athena FIBRICOR fenofibric acid TABLET;ORAL 022418-002 Aug 14, 2009 RX Yes Yes   Start Trial   Start Trial   Start Trial
Athena FIBRICOR fenofibric acid TABLET;ORAL 022418-002 Aug 14, 2009 RX Yes Yes   Start Trial   Start Trial   Start Trial
Athena FIBRICOR fenofibric acid TABLET;ORAL 022418-001 Aug 14, 2009 RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
AstraZeneca
Express Scripts
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.